Related Experiment Video
Updated: Jan 27, 2026

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
Published on: November 12, 2010
Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
Annie Mayence1, Jean Jacques Vanden Eynde2
1Haute Ecole Provinciale de Hainaut-Condorcet, 7330 Saint-Ghislain, Belgium. annie.mayence@alumini.umons.ac.be.
Abstract:
In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.
More Related Videos
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Feedback Inhibition
Molecules and Compounds
Receptor Tyrosine Kinases

